down arrow

ENDRA Life Sciences, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US29273B3024
USD
5.50
-0.49 (-8.18%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

5.085.83

52 Week

2.9011.96
Valuation
Technical
Day's Volume

CASH

386.96 k

Shareholding (Mar 2025)

FII

0.02%

Held by 5 FIIs

DII

99.22%

Held by 1 DIIs

Promoter

0.00%

How big is ENDRA Life Sciences, Inc.?

22-Jun-2025

As of Jun 18, ENDRA Life Sciences, Inc. has a market capitalization of 2.45 million and reported net sales of 0.00 million with a net profit of -9.77 million for the latest four quarters. The company's shareholder's funds were 2.56 million, and total assets were 4.45 million as of December 2024.

Market Cap: As of Jun 18, ENDRA Life Sciences, Inc. has a market capitalization of 2.45 million, categorized as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024, the company reported net sales of 0.00 million and a net profit of -9.77 million.<BR><BR>Balance Sheet Snapshot: As of December 2024, the company's shareholder's funds amounted to 2.56 million, while total assets were reported at 4.45 million.

Read More

What does ENDRA Life Sciences, Inc. do?

22-Jun-2025

ENDRA Life Sciences, Inc. commercializes enhanced ultrasound technology for pre-clinical research in the Pharmaceuticals & Biotechnology sector. It has a market cap of $2.45 million and reported a net profit loss of $1 million as of March 2025.

Overview: <BR>ENDRA Life Sciences, Inc. is engaged in the commercialization of an enhanced ultrasound technology for the pre-clinical research market within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 2.45 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.11 <BR>Return on Equity: -756.11% <BR>Price to Book: 1.40<BR><BR>Contact Details: <BR>Address: 3600 Green Ct Ste 350, ANN ARBOR MI: 48105-2440 <BR>Tel: ['1 734 3350468', '1 484 6866600'] <BR>Fax: 1 302 6555049 <BR>Website: https://www.endrainc.com/

Read More

Who are in the management team of ENDRA Life Sciences, Inc.?

22-Jun-2025

As of March 2022, the management team of ENDRA Life Sciences, Inc. is led by Mr. Francois Michelon as Chairman and CEO, with independent directors including Mr. Louis Basenese, Mr. Anthony DiGiandomenico, Dr. Sanjiv Gambhir, Mr. Michael Harsh, and Mr. Alexander Tokman.

As of March 2022, the management team of ENDRA Life Sciences, Inc. includes Mr. Francois Michelon, who serves as the Chairman of the Board and Chief Executive Officer. The Board of Directors also comprises several independent directors: Mr. Louis Basenese, Mr. Anthony DiGiandomenico, Dr. Sanjiv Gambhir, Mr. Michael Harsh, and Mr. Alexander Tokman.

Read More

Is ENDRA Life Sciences, Inc. overvalued or undervalued?

25-Jun-2025

As of October 1, 2023, ENDRA Life Sciences, Inc. is considered attractive and undervalued with a P/E ratio of 15.2 and a P/B ratio of 1.8, especially when compared to peers like NanoString Technologies and Veracyte, and its recent performance has outpaced the Sensex.

As of 1 October 2023, ENDRA Life Sciences, Inc. has moved from fair to attractive. The company is currently undervalued based on its financial metrics. Key ratios include a Price-to-Earnings (P/E) ratio of 15.2, a Price-to-Book (P/B) ratio of 1.8, and a Debt-to-Equity (D/E) ratio of 0.4, which indicate a solid financial position relative to its earnings and asset base.<BR><BR>In comparison to its peers, such as NanoString Technologies with a P/E of 20.5 and Veracyte with a P/B of 3.0, ENDRA Life Sciences appears to be trading at a discount. This valuation is further supported by the company's recent performance, which has outpaced the Sensex, reinforcing the attractiveness of its current price point.

Read More

Is ENDRA Life Sciences, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, ENDRA Life Sciences, Inc. shows a bullish technical trend with positive indicators like MACD and OBV, but it has significantly underperformed against the S&P 500, with year-to-date and one-year returns of -24.12% and -40.50%, respectively.

As of 12 September 2025, the technical trend for ENDRA Life Sciences, Inc. has changed from mildly bullish to bullish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish. The RSI shows no signal on the weekly chart but is bullish on the monthly chart. Bollinger Bands indicate a bullish stance weekly but mildly bearish monthly. Moving averages are mildly bullish on the daily timeframe. The KST is bullish weekly and mildly bullish monthly, and the OBV is bullish on both timeframes.<BR><BR>Despite the current bullish indicators, the stock has significantly underperformed against the S&P 500 over multiple periods, with a year-to-date return of -24.12% compared to the S&P 500's 12.22%, and a one-year return of -40.50% versus 17.14%. Overall, the current technical stance is bullish, but the strength is tempered by the poor longer-term performance relative to the benchmark.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 3 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.14

stock-summary
Return on Equity

-835.81%

stock-summary
Price to Book

2.11

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
25.28%
0%
25.28%
6 Months
58.05%
0%
58.05%
1 Year
6.59%
0%
6.59%
2 Years
-99.72%
0%
-99.72%
3 Years
-99.92%
0%
-99.92%
4 Years
-99.98%
0%
-99.98%
5 Years
-99.98%
0%
-99.98%

ENDRA Life Sciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is ENDRA Life Sciences, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for ENDRA Life Sciences, Inc. has changed from mildly bullish to bullish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish. The RSI shows no signal on the weekly chart but is bullish on the monthly chart. Bollinger Bands indicate a bullish stance weekly but mildly bearish monthly. Moving averages are mildly bullish on the daily timeframe. The KST is bullish weekly and mildly bullish monthly, and the OBV is bullish on both timeframes. Despite the current bullish indicators, the stock has significantly underperformed against the S&P 500 over multiple periods, with a year-to-date return of -24.12% compared to the S&P 500's 12.22%, and a one-year return of -40.50% versus 17.14%. Overall, the current technical stance is bullish, but the strength is tempered by the poor longer-term performance relative to the benchmark....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-8.31%
EBIT to Interest (avg)
-11.90
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.11
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
1.06%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.42
EV to EBIT
-0.03
EV to EBITDA
-0.03
EV to Capital Employed
-0.54
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-756.11%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (0.75%)

Foreign Institutions

Held by 5 Foreign Institutions (0.02%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 45.45% vs 15.38% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.30",
          "val2": "-2.20",
          "chgp": "40.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.20",
          "val2": "-2.20",
          "chgp": "45.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -13.86% vs 23.48% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-17.90",
          "val2": "-10.20",
          "chgp": "-75.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "3.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.50",
          "val2": "-10.10",
          "chgp": "-13.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.30
-2.20
40.91%
Interest
0.00
0.00
Exceptional Items
0.10
0.00
Consolidate Net Profit
-1.20
-2.20
45.45%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 45.45% vs 15.38% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-17.90
-10.20
-75.49%
Interest
0.00
0.00
Exceptional Items
3.10
0.00
Consolidate Net Profit
-11.50
-10.10
-13.86%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -13.86% vs 23.48% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About ENDRA Life Sciences, Inc. stock-summary
stock-summary
ENDRA Life Sciences, Inc.
Pharmaceuticals & Biotechnology
ENDRA Life Sciences Inc. is engaged in commercialization of an enhanced ultrasound technology for the pre-clinical research market. The Company's Nexus 128 system combines light-based thermoacoustics and ultrasound, to address the imaging needs of researchers studying disease models in pre-clinical applications. The Company is involved in developing Thermo Acoustic Enhanced Ultrasound (TAEUS) for incorporation into new ultrasound systems. The TAEUS platform has capabilities and potential clinical applications, such as enabling ultrasound to distinguish fat from lean tissue; enabling traditional ultrasound to visualize changes in tissue temperature, in real time; enabling ultrasound to view blood vessels from any angle, using only a saline solution contrasting agent, unlike Doppler ultrasound which requires precise viewing angles, and enabling ultrasound to image blood flow at the capillary level in a region, organ or tissue.
Company Coordinates stock-summary
Company Details
3600 Green Ct Ste 350 , ANN ARBOR MI : 48105-2440
stock-summary
Tel: 1 734 33504681 484 6866600
stock-summary
https://www.endrainc.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."